|Bid||36.59 x 900|
|Ask||36.59 x 1100|
|Day's Range||36.00 - 37.39|
|52 Week Range||13.85 - 46.93|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.00|
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $40.00 per share pursuant to its existing shelf registration statement, for gross proceeds of $230.0 million. The number of shares issued at closing included the exercise in full of the underwriters’ option to purchase 750,000 additional shares. Net proceeds to NanoString from the offering were approximately $215.7 million after deducting underwriting discounts and commissions and the estimated expenses of the offering. NanoString intends to use the net proceeds of the offering for working capital and general corporate purposes.
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis tools, today announced a key milestone in their partnership to develop new analysis tools to accelerate research on NanoString’s nCounter® Analysis System. After successful completion of an Early Access Program announced in May, the parties are expanding access to new analysis capabilities to all nCounter users. The new analysis functionality is built into ROSALIND®, OnRamp’s cloud-based analysis platform that facilitates data visualization, exploration and collaboration. NanoString will support ROSALIND as a preferred analysis solution for nCounter data and make it broadly available to users of the nCounter Analysis System.
NanoString announces pricing of upsized public stock offering.